{"title":"液-液相分离GPS2-LATS1通过重编程脂质代谢促进结直肠癌进展。","authors":"Yuliang Ren, Junjie Chen, Xiangrong Zhan, Songran Sheng, Yifan Zhong, Manxiang Gu, Xuewen Liu, Liang Zhang, Lei Bao, Yuan Si, Ying Liu","doi":"10.1038/s41388-025-03498-7","DOIUrl":null,"url":null,"abstract":"Aberrant lipid metabolism is a hallmark of colorectal cancer (CRC), yet the underlying regulatory mechanisms remain incompletely understood. Here, we identified G protein pathway suppressor 2 (GPS2) as a pivotal oncogenic driver that orchestrates lipid metabolic reprogramming to fuel CRC progression. Clinically, GPS2 is overexpressed in CRC and is correlated with aggressive phenotypes. Functionally, GPS2 depletion inhibits tumor growth in vitro and in vivo, whereas its overexpression accelerates malignancy. Mechanistically, GPS2 dual-regulates lipid metabolism by facilitating the nuclear translocation of sterol regulatory element-binding protein 1 (SREBP1) to activate lipid synthesis and by increasing peroxisome proliferator-activated receptor α (PPARα) transcription to promote fatty acid oxidation. Crucially, we revealed that GPS2 undergoes liquid-liquid phase separation (LLPS) in CRC cells, where it forms biomolecular condensates that promote oncogenic signaling. Through its coiled-coil domain, phase-separated GPS2 directly interacts with the C-terminal kinase domain of large tumor suppressor 1 (LATS1), a core kinase of the Hippo pathway, inducing LLPS of LATS1 and suppressing its activity. This inactivation releases YAP, which in turn amplifies SREBP1/PPARα-driven lipid metabolism. Rescue experiments confirmed that YAP reconstitution restores SREBP1 nuclear translocation and PPARα transcription upon GPS2 loss, establishing the LATS1-YAP axis as the central effector of GPS2-mediated lipid metabolic programming. Our study delineates a novel phase separation-dependent mechanism whereby GPS2 spatially reorganizes LATS1-YAP signaling to reprogram lipid metabolism and promote CRC progression, suggesting potential therapeutic targets for metabolic intervention in CRC.","PeriodicalId":19524,"journal":{"name":"Oncogene","volume":"44 39","pages":"3741-3754"},"PeriodicalIF":7.3000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Liquid-liquid phase separation of GPS2-LATS1 promotes colorectal cancer progression by reprogramming lipid metabolism\",\"authors\":\"Yuliang Ren, Junjie Chen, Xiangrong Zhan, Songran Sheng, Yifan Zhong, Manxiang Gu, Xuewen Liu, Liang Zhang, Lei Bao, Yuan Si, Ying Liu\",\"doi\":\"10.1038/s41388-025-03498-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aberrant lipid metabolism is a hallmark of colorectal cancer (CRC), yet the underlying regulatory mechanisms remain incompletely understood. Here, we identified G protein pathway suppressor 2 (GPS2) as a pivotal oncogenic driver that orchestrates lipid metabolic reprogramming to fuel CRC progression. Clinically, GPS2 is overexpressed in CRC and is correlated with aggressive phenotypes. Functionally, GPS2 depletion inhibits tumor growth in vitro and in vivo, whereas its overexpression accelerates malignancy. Mechanistically, GPS2 dual-regulates lipid metabolism by facilitating the nuclear translocation of sterol regulatory element-binding protein 1 (SREBP1) to activate lipid synthesis and by increasing peroxisome proliferator-activated receptor α (PPARα) transcription to promote fatty acid oxidation. Crucially, we revealed that GPS2 undergoes liquid-liquid phase separation (LLPS) in CRC cells, where it forms biomolecular condensates that promote oncogenic signaling. Through its coiled-coil domain, phase-separated GPS2 directly interacts with the C-terminal kinase domain of large tumor suppressor 1 (LATS1), a core kinase of the Hippo pathway, inducing LLPS of LATS1 and suppressing its activity. This inactivation releases YAP, which in turn amplifies SREBP1/PPARα-driven lipid metabolism. Rescue experiments confirmed that YAP reconstitution restores SREBP1 nuclear translocation and PPARα transcription upon GPS2 loss, establishing the LATS1-YAP axis as the central effector of GPS2-mediated lipid metabolic programming. Our study delineates a novel phase separation-dependent mechanism whereby GPS2 spatially reorganizes LATS1-YAP signaling to reprogram lipid metabolism and promote CRC progression, suggesting potential therapeutic targets for metabolic intervention in CRC.\",\"PeriodicalId\":19524,\"journal\":{\"name\":\"Oncogene\",\"volume\":\"44 39\",\"pages\":\"3741-3754\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncogene\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41388-025-03498-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncogene","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41388-025-03498-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Liquid-liquid phase separation of GPS2-LATS1 promotes colorectal cancer progression by reprogramming lipid metabolism
Aberrant lipid metabolism is a hallmark of colorectal cancer (CRC), yet the underlying regulatory mechanisms remain incompletely understood. Here, we identified G protein pathway suppressor 2 (GPS2) as a pivotal oncogenic driver that orchestrates lipid metabolic reprogramming to fuel CRC progression. Clinically, GPS2 is overexpressed in CRC and is correlated with aggressive phenotypes. Functionally, GPS2 depletion inhibits tumor growth in vitro and in vivo, whereas its overexpression accelerates malignancy. Mechanistically, GPS2 dual-regulates lipid metabolism by facilitating the nuclear translocation of sterol regulatory element-binding protein 1 (SREBP1) to activate lipid synthesis and by increasing peroxisome proliferator-activated receptor α (PPARα) transcription to promote fatty acid oxidation. Crucially, we revealed that GPS2 undergoes liquid-liquid phase separation (LLPS) in CRC cells, where it forms biomolecular condensates that promote oncogenic signaling. Through its coiled-coil domain, phase-separated GPS2 directly interacts with the C-terminal kinase domain of large tumor suppressor 1 (LATS1), a core kinase of the Hippo pathway, inducing LLPS of LATS1 and suppressing its activity. This inactivation releases YAP, which in turn amplifies SREBP1/PPARα-driven lipid metabolism. Rescue experiments confirmed that YAP reconstitution restores SREBP1 nuclear translocation and PPARα transcription upon GPS2 loss, establishing the LATS1-YAP axis as the central effector of GPS2-mediated lipid metabolic programming. Our study delineates a novel phase separation-dependent mechanism whereby GPS2 spatially reorganizes LATS1-YAP signaling to reprogram lipid metabolism and promote CRC progression, suggesting potential therapeutic targets for metabolic intervention in CRC.
期刊介绍:
Oncogene is dedicated to advancing our understanding of cancer processes through the publication of exceptional research. The journal seeks to disseminate work that challenges conventional theories and contributes to establishing new paradigms in the etio-pathogenesis, diagnosis, treatment, or prevention of cancers. Emphasis is placed on research shedding light on processes driving metastatic spread and providing crucial insights into cancer biology beyond existing knowledge.
Areas covered include the cellular and molecular biology of cancer, resistance to cancer therapies, and the development of improved approaches to enhance survival. Oncogene spans the spectrum of cancer biology, from fundamental and theoretical work to translational, applied, and clinical research, including early and late Phase clinical trials, particularly those with biologic and translational endpoints.